Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers

This invention concerns spiro azepane-oxazolidinones as voltage gated Kv1.3 potassium channel blockers, pharmaceutical compositions containing these compounds, methods for preparing the compounds, methods for preparing novel intermediates useful for their synthesis, and methods for preparing composi...

Full description

Saved in:
Bibliographic Details
Main Authors KOEHLER, KONRAD F, NUNEZ GARCIA, SARA, MLINARIC, MICHAEL, LANGE, JOSEPHUS H. M, SMID, PIETER, WEGENER, ELMAR
Format Patent
LanguageChinese
English
Published 16.07.2010
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:This invention concerns spiro azepane-oxazolidinones as voltage gated Kv1.3 potassium channel blockers, pharmaceutical compositions containing these compounds, methods for preparing the compounds, methods for preparing novel intermediates useful for their synthesis, and methods for preparing compositions. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect diabetes and inflammatory neuropathies, including T-cell mediated autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. The compounds have formula (1): wherein the symbols have the meanings given in the specification.
Bibliography:Application Number: TW200998142079